Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01139762 · ClinicalTrials.gov registry record · Phase 3
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 696
- Enrollment target
NCT01139762 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 696 participants.
The verdict
NCT01139762, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 696 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy and safety of once daily tadalafil when taken with finasteride as a treatment for men with signs and symptoms of Benign Prostatic Hyperplasia and demonstrable prostate enlargement.
Interventions
- DRUG Placebo
- DRUG Finasteride
- DRUG Tadalafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 696 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01139762
The ClinicalTrials.gov registry entry for NCT01139762 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 696 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01139762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01139762 about?
NCT01139762 is a clinical study titled "A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms". The purpose of this study is to investigate the efficacy and safety of once daily tadalafil when taken with finasteride as a treatment for men with signs and symptoms of Benign Prostatic Hyperplasia and demonstrable prostate enlargement.
What is the current status of trial NCT01139762?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 696 participants. The study started on 2010-09. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01139762?
The interventions under investigation include: Placebo (DRUG), Finasteride (DRUG), Tadalafil (DRUG).
Who is sponsoring clinical trial NCT01139762?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.